



October 22, 2024

**BSE Limited**  
P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

Dear Sir / Madam,

In terms of Regulation 30 of the SEBI Listing Regulations, we wish to inform that ICRA Limited ('ICRA'), has assigned rating to Piramal Pharma Limited as per the details given below in connection with prospective commercial paper:

<b>Type of Rating</b>	<b>Rating</b>	<b>Rating Action</b>
Prospective commercial paper	[ICRA] A1+	Assigned

We request you to take the above information on record.

Thanking you,

Yours truly,  
For **Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000; Email: [shareholders.ppl@piramal.com](mailto:shareholders.ppl@piramal.com)

[piramalpharma.com](http://piramalpharma.com)